Our real-life experience shows that the long-term treatment with adalimumab is effective and well tolerated in psoriatic patients, including overweight/obese, elderly and anti-TNF-experienced subjects.
No takes yet. Share an insight, caveat, or question.
Chiricozzi et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: